More Arovella Therapeutics Limited news
Arovella Therapeutics LimitedASX: ALA

Business Development Update

Jul 15, 2018 at 10:44 PM EDT · Issued by Arovella Therapeutics Limited

Filed with ASX · Jul 15, 2018 at 10:44 PM EDT

On 6ix: 6ix.com/news/business-development-update-4

Arovella Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Arovella Therapeutics Limited on 6ix

Story so far

  • SUDA progresses business development at BIO 2015Feb 11, 2016

Earlier from Arovella Therapeutics

  • Anagrelide UpdateJul 11, 2018
  • Prospectus for a Renounceable Pro Rata OfferJul 1, 2018
  • Settlement with HC Berlin Pharma and Rights IssueJul 1, 2018
  • Shareholder UpdateJun 20, 2018
  • SUDA Expands Patent Coverage For SildenafilJun 17, 2018

Later from Arovella Therapeutics

  • SUDA Achieves TGA GMP LicenceAug 20, 2018
  • Request for Trading HaltSep 11, 2018
  • Appendix 4C, Market Update and Top 20Oct 28, 2018
  • SUDA Signs Agreement For SUD-001H For US MarketNov 7, 2018
  • ZolpiMist Market UpdateNov 12, 2018
All Arovella Therapeutics news releases↗

Follow Arovella Therapeutics into a list and get an email when it puts out news.

Follow Arovella Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer